Premenstrual dysphoric disorder-Gynecological diagnostics and treatment in an interdisciplinary context

被引:0
作者
Dorn, Almut [1 ]
Rohde, Anke [2 ]
Schwenkhagen, Anneliese [3 ]
机构
[1] Praxis Gynakol Psychosomat, Klingenberg 2, D-22587 Hamburg, Germany
[2] Univ Bonn, Gynakol Psychosomat, Bonn, Germany
[3] HORMONE HAMBURG, Praxis Gynakol Endokrinol, Hamburg, Germany
来源
GYNAKOLOGISCHE ENDOKRINOLOGIE | 2025年 / 23卷 / 01期
关键词
Premenstrual syndrome; Premenstrual dysphoric disorder/etiology; Hormone therapy; Antidepressive agents; Psychotherapy; VENLAFAXINE; WOMEN;
D O I
10.1007/s10304-024-00606-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Premenstrual dysphoric disorder (PMDD) is a gynecologically relevant illness and typical features are predominantly severe emotional and sometimes physical symptoms that occur in the luteal phase. The PMDD is the most severe form of the premenstrual syndrome (PMS). As approximately 3-8% of women in childbearing age are affected, it represents an important challenge in gynecological practices. The PMDD is still a little known, underdiagnosed and insufficiently treated disorder. This article provides an overview of the symptoms (as demarcation from PMS) and the diagnostic criteria of PMDD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Statistical Classification of Diseases and Related Health Problems (ICD-11). It illuminates evidence-based treatment approaches, which encompass hormone therapy, the use of certain antidepressant agents and psychotherapeutic procedures. Even if the etiology is not yet completely clarified, there are effective treatment approaches. An interdisciplinary approach is recommended for the successful treatment of this disease.
引用
收藏
页码:3 / 13
页数:11
相关论文
共 35 条
  • [1] Battey R, 1880, Br Med J, V1, P510
  • [2] bfarm.de, BFARM ICD 11 DEUTSCH
  • [3] Selective serotonin reuptake inhibitors for premenstrual syndrome
    Brown, Julie
    O'Brien, Patrick Michael Shaughn
    Marjoribanks, Jane
    Wyatt, Katrina
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [4] Bundesarztekammer (BAK) Kassenarztliche Bundesvereinigung (KBV) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), 2022, NATIONALE VERSORGUNG
  • [5] Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder
    Cohen, LS
    Soares, CN
    Lyster, A
    Cassano, P
    Brandes, M
    Leblanc, GA
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (05) : 540 - 543
  • [6] Dennerstein Lorraine, 2012, Menopause Int, V18, P48, DOI 10.1258/mi.2012.012013
  • [7] Dilling H., 2015, INT KLASSIFIKATION P
  • [8] Dorn A., 2023, PMDS ALS HERAUSFORDE, DOI [10.17433/978-3-17-044561-1, DOI 10.17433/978-3-17-044561-1]
  • [9] DSM-III-R. American Psychiatric Association (APA), 1989, DIAGNOSTISCHES STATI
  • [10] Neuroimaging the menstrual cycle: A multimodal systematic review
    Dubol, Manon
    Epperson, C. Neill
    Sacher, Julia
    Pletzer, Belinda
    Derntl, Birgit
    Lanzenberger, Rupert
    Sundstrom-Poromaa, Inger
    Comasco, Erika
    [J]. FRONTIERS IN NEUROENDOCRINOLOGY, 2021, 60